The Tromsø Study, initiated in 1974 in response to the high cardiovascular disease mortality rates in Northern Norway, has since evolved into a series of seven studies conducted at 7-8 year intervals. The eighth Tromsø Study is scheduled for 2025-2026 and will involve 4,000 participants with elevated NT-proBNP levels. Participants will be randomized to atrial fibrillation screening using ECG247. Outcomes in the intervention group will be compared to those in the control group regarding stroke incidence and mortality over a six-year follow-up period.

For ECG247, it is a vote of confidence that another leading research community chooses to use Norwegian medical technology. ECG247 is also in use in the Norwegian national atrial fibrillation screening study NORSCREEN and in the Nord-Trøndelag Health Study (HUNT). The ECG247 is highly cost-effective and requires minimal personnel resources.